Health Care Services

CH BIOTECH SER

China Biosciences Services Reports FY25 Revenue Up 4.2%, Loss Narrowed 65.3%

CH BIOTECH SER released FY2025 9 Months Earnings on March 27 (BJT), actual revenue HKD 56.19 M, actual EPS HKD -0.0513

CH BIOTECH SER released FY2025 Q3 earnings on March 27, 2026 (BJT), with actual revenue of HKD 17.32 M and EPS of HKD -0.0185

CH BIOTECH SER released FY2025 Q4 earnings on March 27 During-Market (BJT), actual revenue HKD 17.32 M, actual EPS HKD -0.0185

CH BIOTECH SER released FY2025 earnings on March 27 During-Market (BJT), actual revenue HKD 73.5 M, actual EPS HKD -0.07

CH BIOTECH SER to Release FY2025 Earnings Report on March 27, 2026 During-Market BJT

China Bioscience Services Anticipates a Net Loss of No More Than HKD 100 Million for the Fiscal Year

China Bioscience Services Completes $35M Convertible Bond Issuance and Adjusts Existing Bonds

China Biosciences Service Holdings to Hold Extraordinary General Meeting to Approve Convertible Bond Issuance

China Biosciences Service's Boron Neutron Hospital System Achieves First Beam and Enters Final Clinical Debugging Stage

CH BIOTECH SER released FY2025 Q1 earnings on August 27 (BJT), actual revenue HKD 19.44 M, actual EPS HKD -0.0164

CH BIOTECH SER released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), actual revenue HKD 38.87 M, actual EPS HKD -0.0328

CH BIOTECH SER released FY2025 Q2 earnings on August 27 During-Market BJT, actual revenue HKD 19.44 M, actual EPS HKD -0.0164

CH BIOTECH SER to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

AXA 安盛 Signs MOU with China Biotech Service for Innovative Cancer Tech Cooperation

China Bioscience Service Invests in Dynamic Healthcare via Huada Songhe

China Bioscience Services Collaborates with Multiple Insurers on BNCT Insurance Product

China Biosciences Services Enters MOU to Promote Boron Neutron Therapy Drugs

CBTG Subsidiary to Present LY007 Clinical Trial Results at International Conferences

CH BIOTECH SER released FY2024 9 Months Earnings on March 28 (BJT), with actual revenue of 51.48 M HKD and EPS of -0.1436 HKD

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

01177

08037

512010

159506

159929

Sino Biopharmaceutical's subsidiary LaNova Medicines presented promising early clinical data for MK-2010/LM-299, a PD-1/VEGF bispecific cancer drug licensed to Merck. In a Phase 1/2 study with 112 patients, the drug demonstrated a manageable safety profile and notable efficacy signals, particularly in non-small cell lung cancer, with an overall response rate of 55% at 20 mg/kg. This development enhances Sino Biopharmaceutical's position in oncology and underscores the strategic partnership with Merck. Analysts rate the stock as a Buy with a target price of HK$8.70.

Tip Ranks

SBP GROUP

E Fund CSI 300 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Merck

Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck

516820

588250

159849

560600

The next blockbuster BD deal is on its way

- China Biologic Products (01177.HK) reported a 2025 total revenue of 31.83 billion CNY, a year-on-year increase of 10.3%, with adjusted net profit rising 31.4% to 4.54 billion CNY.  
- The company has undertaken significant acquisitions, including a $950 million purchase of Auron Biopharma and a $1.2 billion acquisition of Hegia, positioning itself uniquely in the domestic pharmaceutical market.  
- With a target of launching nearly 20 innovative products by 2028, including advancements in oncology and chronic disease treatment, China Biologic aims for substantial international revenue growth through a dual strategy of acquisitions and global business development.

Wallstreetcn

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Lishengpharma

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM

The Heilongjiang Provincial Government has issued policies to support the high-quality development of the biomanufacturing industry, encouraging leading enterprises to form industry technology innovation alliances and research institutes, strengthening collaboration in the industrial chain, promoting independent innovation among small and medium-sized enterprises, enhancing specialization capabilities, forming an industrial ecosystem, and building a national-level biomanufacturing cluster

Heilongjiang: Encouraging leading enterprises in biomanufacturing to take the lead in forming industry technology innovation alliances, industry technology research institutes, and other innovation consortia

01093

01801

02269

08189

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

CSPC PHARMA

INNOVENT BIO

WUXI BIO

TEDA BIOMEDICAL

QYUNS-B

CH BIOTECH SER announced that its wholly-owned subsidiary Pengbo (Hainan) has signed a loan agreement with Hainan Rural Commercial Bank, with a maximum loan amount of 180 million yuan. The loan will be used to construct a boron neutron capture therapy center, expected to open by the end of 2025, providing treatment services for cancer patients. The company plans to develop a network of treatment centers covering China with the support of the Boao Lecheng Pilot Zone, creating more revenue

Zhitong

CH BIOTECH SER's subsidiary has been granted a loan with a principal amount of up to 180 million yuan

CH BIOTECH SER announced its mid-term results for 2025, with revenue of HKD 38.872 million, a year-on-year increase of 19.79%; the loss attributable to shareholders was HKD 32.006 million, a year-on-year narrowing of 59.95%; the loss per share was HKD 0.033. The improvement in loss was mainly due to the successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 13.7 million in insurance compensation income

CH BIOTECH SER announced its interim results, with a loss attributable to shareholders of HKD 32.06 million, a year-on-year narrowing of 59.95%

CH BIOTECH SER expects that the loss attributable to shareholders in the middle of 2025 will not exceed HKD 33 million, a year-on-year decrease of approximately 59%. The main reasons include successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 14 million in insurance compensation income

CH BIOTECH SER expects a mid-term loss attributable to shareholders to decrease by approximately 59% year-on-year

CH BIOTECH SER(08037.HK)